Continuum Clinical has introduced its new MERIS Total Engagement Solution to offer streamlined predictability in clinical trials.

The new solution is a globally compliant clinical trial enrolment and retention products suite that enables a seamless experience for research sites and study participants.

It also produces real-time performance data for sponsors.

The MERIS Total Engagement Solution interacts with participants throughout their clinical trial journey and provides opportunities for sponsors to identify exact barriers which are impacting retention and enrolment.

It includes the MERIS Enrollment globally compliant technology solution that pre-screens and connects study participants, who are qualified, to research sites.

The MERIS Retention enables direct-to-patient interaction throughout screening and enrolment for reminding them of upcoming visits, real-time feedback collection, and encourage patients to take part to improve their trial experience.

The MERIS Total Engagement Solution also includes MERIS Analytics that visualises, captures, and simplifies the data, which is collected from the Enrollment and Retention Solutions that offers real-time performance measurements.

Continuum Clinical president Neil Weisman said: “We developed MERIS based on both data and first-hand observations we have seen as clinical trials continue to evolve.

“MERIS allows anyone who is responsible for enrolling and retaining patients in clinical trials to pinpoint specific risks that may impact enrolment and retention.

“This enables precise, real-time course corrections that will help avoid costly delays and identify enrolment problems without guesswork.”

With MERIS, users will be able to optimise their advertising spend, improve ROI, and decrease the randomisation cost.

It also helps to identify participants who are at risk of dropping out of a trial.

The solution uses advanced Cloud technology for providing the infrastructure which is required to manage a patient recruitment campaign.